Evidence map›Paper›PMID 26918757›Full record

ArticlePloS one2016

MLIF Alleviates SH-SY5Y Neuroblastoma Injury Induced by Oxygen-Glucose Deprivation by Targeting Eukaryotic Translation Elongation Factor 1A2.

Qiuzhen Zhu, Yuefan Zhang, Yulan Liu, Hao Cheng, Jing Wang, Yue Zhang, Yaocheng Rui, Tiejun Li

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Qiuzhen ZhuDepartment of Pharmacology, College of Pharmacy, Second Military Medical University, Shanghai, China.
Yuefan ZhangDepartment of Pharmacology, College of Pharmacy, Second Military Medical University, Shanghai, China.
Yulan LiuDepartment of Pharmacology, College of Pharmacy, Second Military Medical University, Shanghai, China.
Hao ChengCollege of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, China.
Jing WangCollege of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, China.
Yue ZhangCollege of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, China.
Yaocheng RuiDepartment of Pharmacology, College of Pharmacy, Second Military Medical University, Shanghai, China.
Tiejun LiDepartment of Pharmacology, College of Pharmacy, Second Military Medical University, Shanghai, China.
Second Military Medical University · CNAnhui University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monocyte locomotion inhibitory factor (MLIF), a heat-stable pentapeptide, has been shown to exert potent anti-inflammatory effects in ischemic brain injury. In this study, we investigated the neuroprotective action of MLIF against oxygen-glucose deprivation (OGD)-induced injury in human neuroblastoma SH-SY5Y cells. MTT assay was used to assess cell viability, and flow cytometry assay and Hoechst staining were used to evaluate apoptosis. LDH assay was used to exam necrosis. The release of inflammatory cytokines was detected by ELISA. Levels of the apoptosis associated proteins were measured by western blot analysis. To identify the protein target of MLIF, pull-down assay and mass spectrometry were performed. We observed that MLIF enhanced cell survival and inhibited apoptosis and necrosis by inhibiting p-JNK, p53, c-caspase9 and c-caspase3 expression. In the microglia, OGD-induced secretion of inflammatory cytokines was markedly reduced in the presence of MLIF. Furthermore, we found that eukaryotic translation elongation factor 1A2 (eEF1A2) is a downstream target of MLIF. Knockdown eEF1A2 using short interfering RNA (siRNA) almost completely abrogated the anti-apoptotic effect of MLIF in SH-SY5Y cells subjected to OGD, with an associated decrease in cell survival and an increase in expression of p-JNK and p53. These results indicate that MLIF ameliorates OGD-induced SH-SY5Y neuroblastoma injury by inhibiting the p-JNK/p53 apoptotic signaling pathway via eEF1A2. Our findings suggest that eEF1A2 may be a new therapeutic target for ischemic brain injury.

Indexed as

AnimalsAnti-Inflammatory AgentsApoptosisBrain InjuriesBrain IschemiaCaspase 3Caspase 9Cell HypoxiaCell Line, TumorCell SurvivalCytokinesGlucoseHumansJNK Mitogen-Activated Protein KinasesMiceMicrogliaAnti-Inflammatory AgentsCaspase 3Caspase 9CytokinesEEF1A2 protein, humanGlucoseJNK Mitogen-Activated Protein Kinasesmonocyte locomotion inhibitory factorNeuroprotective AgentsOligopeptidesPeptide Elongation Factor 1RNA, Small InterferingTumor Suppressor Protein p53

Identifiers

PMID26918757
PMCPMC4769291
OpenAlexW2278567865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.